{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:39:39Z","timestamp":1792787979367,"version":"4.5.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T00:00:00Z","timestamp":1784073600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T00:00:00Z","timestamp":1791504000000},"content-version":"vor","delay-in-days":86,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Wuhan Municipal Traditional Chinese Medicine Research Project","award":["WZ24A23"],"award-info":[{"award-number":["WZ24A23"]}]},{"name":"National Natural Science Foundation of China","award":["82302956"],"award-info":[{"award-number":["82302956"]}],"id":[{"id":"https:\/\/ror.org\/01h0zpd94","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Fruquintinib is an established treatment option for patients with advanced colorectal cancer (CRC) who have progressed after standard therapies, including oxaliplatin- and irinotecan-based chemotherapy. Although this population generally shows limited sensitivity to anti\u2013PD-1\/PD-L1 immunotherapy, the combination of fruquintinib and PD-1 inhibitors has been widely used in clinical practice. In this reconstructed patient-level meta-analysis, we aimed to characterize survival outcomes reported in retrospective real-world studies evaluating fruquintinib combined with PD-1 inhibitors.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Public databases, including PubMed, Web of Science, Embase, and the Cochrane Central Register of Controlled Trials (CENTRAL), were systematically searched on January 26, 2026. Patient-level survival data were reconstructed from published Kaplan\u2013Meier curves using the \u201cIPDfromKM\u201d package in R. The \u201csurvival\u201d package was used to analyze reconstructed overall survival (OS) and progression-free survival (PFS). The \u201cmeta\u201d package was used to pool objective response rate (ORR) and disease control rate (DCR).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 10 retrospective studies involving 609 patients were included, all conducted in China. The reported median OS ranged from 14.9 to 19.5 months, and the pooled median OS was 15.7 months. The reported median PFS ranged from 3.8 to 7.0 months, and the pooled median PFS was 5.5 months. The pooled ORR was 12% (95% CI, 7\u201318), and the pooled DCR was 74% (95% CI, 68\u201381). No significant publication bias was detected in the analyses of response rates.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This reconstructed patient-level meta-analysis provides a descriptive summary of reported outcomes associated with fruquintinib combined with PD-1 inhibitors in patients with advanced CRC across retrospective real-world studies. However, safety outcomes were not systematically reported and therefore could not be comprehensively evaluated. Given the absence of a comparator group, the current evidence does not allow assessment of whether the addition of PD-1 inhibitors improves outcomes compared with fruquintinib monotherapy. Prospective randomized controlled trials are warranted to further characterize the clinical outcomes and safety profile of this treatment strategy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12885-026-16420-5","type":"journal-article","created":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T10:06:22Z","timestamp":1784109982000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Treatment outcomes of fruquintinib combined with PD-1 inhibitors in advanced colorectal cancer: a reconstructed patient-level meta-analysis of retrospective real-world studies"],"prefix":"10.1186","volume":"26","author":[{"given":"Yan","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing-Ting","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guo-He","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ru-Bo","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bi-Cheng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,15]]},"reference":[{"issue":"15","key":"16420_CR1","doi-asserted-by":"publisher","first-page":"3100","DOI":"10.1158\/1078-0432.CCR-24-0281","volume":"30","author":"MJ Fusco","year":"2024","unstructured":"Fusco MJ, Casak SJ, Mushti SL, Cheng J, Christmas BJ, Thompson MD, Fu W, Wang H, Yoon M, Yang Y, et al. FDA Approval Summary: Fruquintinib for the Treatment of Refractory Metastatic Colorectal Cancer. Clin Cancer Res. 2024;30(15):3100\u20134.","journal-title":"Clin Cancer Res"},{"issue":"10395","key":"16420_CR2","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/S0140-6736(23)00772-9","volume":"402","author":"A Dasari","year":"2023","unstructured":"Dasari A, Lonardi S, Garcia-Carbonero R, Elez E, Yoshino T, Sobrero A, Yao J, Garcia-Alfonso P, Kocsis J, Cubillo Gracian A, et al. Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study. Lancet. 2023;402(10395):41\u201353.","journal-title":"Lancet"},{"key":"16420_CR3","doi-asserted-by":"crossref","unstructured":"Eng C, Dasari A, Lonardi S, Garcia-Carbonero R, Elez E, Yoshino T, Sobrero A, Yao J, Garcia-Alfonso P, Kocsis J et al. Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer: safety analysis of FRESCO-2. Oncologist. 2025;30(3):oyae360.","DOI":"10.1093\/oncolo\/oyae360"},{"issue":"24","key":"16420_CR4","doi-asserted-by":"publisher","first-page":"2735","DOI":"10.1200\/JCO.21.02691","volume":"40","author":"Z Jin","year":"2022","unstructured":"Jin Z, Sinicrope FA. Mismatch Repair-Deficient Colorectal Cancer: Building on Checkpoint Blockade. J Clin Oncol. 2022;40(24):2735\u201350.","journal-title":"J Clin Oncol"},{"key":"16420_CR5","doi-asserted-by":"publisher","first-page":"573547","DOI":"10.3389\/fonc.2021.573547","volume":"11","author":"G Cui","year":"2021","unstructured":"Cui G. The Mechanisms Leading to Distinct Responses to PD-1\/PD-L1 Blockades in Colorectal Cancers With Different MSI Statuses. Front Oncol. 2021;11:573547.","journal-title":"Front Oncol"},{"key":"16420_CR6","doi-asserted-by":"publisher","first-page":"841977","DOI":"10.3389\/fonc.2022.841977","volume":"12","author":"Q Li","year":"2022","unstructured":"Li Q, Cheng X, Zhou C, Tang Y, Li F, Zhang B, Huang T, Wang J, Tu S. Fruquintinib Enhances the Antitumor Immune Responses of Anti-Programmed Death Receptor-1 in Colorectal Cancer. Front Oncol. 2022;12:841977.","journal-title":"Front Oncol"},{"key":"16420_CR7","doi-asserted-by":"crossref","unstructured":"Zhao W, Lei J, Ke S, Chen Y, Xiao J, Tang Z, Wang L, Ren Y, Alnaggar M, Qiu H et al. Fecal microbiota transplantation plus tislelizumab and fruquintinib in refractory microsatellite stable metastatic colorectal cancer: an open-label, single-arm, phase II trial (RENMIN-215). EClinicalMedicine. 2023;66:102315.","DOI":"10.1016\/j.eclinm.2023.102315"},{"key":"16420_CR8","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.ejca.2022.12.004","volume":"181","author":"Y Guo","year":"2023","unstructured":"Guo Y, Zhang W, Ying J, Zhang Y, Pan Y, Qiu W, Fan Q, Xu Q, Ma Y, Wang G, et al. Phase 1b\/2 trial of fruquintinib plus sintilimab in treating advanced solid tumours: The dose-escalation and metastatic colorectal cancer cohort in the dose-expansion phases. Eur J Cancer. 2023;181:26\u201337.","journal-title":"Eur J Cancer"},{"issue":"16","key":"16420_CR9","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1001\/jama.2015.3656","volume":"313","author":"LA Stewart","year":"2015","unstructured":"Stewart LA, Clarke M, Rovers M, Riley RD, Simmonds M, Stewart G, Tierney JF, Group P-ID. Preferred Reporting Items for Systematic Review and Meta-Analyses of individual participant data: the PRISMA-IPD Statement. JAMA. 2015;313(16):1657\u201365.","journal-title":"JAMA"},{"issue":"1","key":"16420_CR10","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1186\/s12874-021-01308-8","volume":"21","author":"N Liu","year":"2021","unstructured":"Liu N, Zhou Y, Lee JJ. IPDfromKM: reconstruct individual patient data from published Kaplan-Meier survival curves. BMC Med Res Methodol. 2021;21(1):111.","journal-title":"BMC Med Res Methodol"},{"issue":"6","key":"16420_CR11","doi-asserted-by":"publisher","first-page":"541","DOI":"10.3892\/ol.2025.15287","volume":"30","author":"Y Peng","year":"2025","unstructured":"Peng Y, Li S, Zhu L. Efficacy and safety of fruquintinib combined with immunotherapy in later-line treatment of metastatic colorectal cancer. Oncol Lett. 2025;30(6):541.","journal-title":"Oncol Lett"},{"key":"16420_CR12","doi-asserted-by":"publisher","first-page":"754881","DOI":"10.3389\/fonc.2021.754881","volume":"11","author":"L Sun","year":"2021","unstructured":"Sun L, Huang S, Li D, Mao Y, Wang Y, Wu J. Efficacy and Safety of Fruquintinib Plus PD-1 Inhibitors Versus Regorafenib Plus PD-1 Inhibitors in Refractory Microsatellite Stable Metastatic Colorectal Cancer. Front Oncol. 2021;11:754881.","journal-title":"Front Oncol"},{"key":"16420_CR13","doi-asserted-by":"publisher","first-page":"1420956","DOI":"10.3389\/fonc.2024.1420956","volume":"14","author":"K Zheng","year":"2024","unstructured":"Zheng K, Zhu X, Xu L, Cao G, Niu C, Yan X, Xu D, Liu W, Bao Q, Wang L, et al. Efficacy and safety of hepatic arterial infusion chemotherapy combined with fruquintinib and tislelizumab for patients with microsatellite stable colorectal cancer liver metastasis following failure of multiple-line therapy. Front Oncol. 2024;14:1420956.","journal-title":"Front Oncol"},{"issue":"6","key":"16420_CR14","doi-asserted-by":"publisher","first-page":"2449","DOI":"10.4251\/wjgo.v16.i6.2449","volume":"16","author":"TQ An","year":"2024","unstructured":"An TQ, Qiu H, Zhou QB, Zong H, Hu S, Lian YG, Zhao RH. Efficacy comparison of fruquintinib, regorafenib monotherapy or plus programmed death-1 inhibitors for microsatellite stable metastatic colorectal cancer. World J Gastrointest Oncol. 2024;16(6):2449\u201362.","journal-title":"World J Gastrointest Oncol"},{"key":"16420_CR15","doi-asserted-by":"publisher","first-page":"929342","DOI":"10.3389\/fonc.2022.929342","volume":"12","author":"W Zhang","year":"2022","unstructured":"Zhang W, Zhang Z, Lou S, Li D, Ma Z, Xue L. Efficacy, safety and predictors of combined fruquintinib with programmed death-1 inhibitors for advanced microsatellite-stable colorectal cancer: A retrospective study. Front Oncol. 2022;12:929342.","journal-title":"Front Oncol"},{"issue":"6","key":"16420_CR16","doi-asserted-by":"publisher","first-page":"2425","DOI":"10.21037\/jgo-23-931","volume":"14","author":"XL Yang","year":"2023","unstructured":"Yang XL, Yin XL, Qu XZ, Guo GY, Zeng YD, Liu W, Jagielski M, Liu ZY, Zhou HJ. Efficacy, safety, and predictors of fruquintinib plus antiprogrammed death receptor-1 (PD-1) antibody in refractory microsatellite stable metastatic colorectal cancer in a real-world setting: a retrospective cohort study. J Gastrointest Oncol. 2023;14(6):2425\u201335.","journal-title":"J Gastrointest Oncol"},{"key":"16420_CR17","doi-asserted-by":"publisher","first-page":"103700","DOI":"10.1016\/j.clon.2024.103700","volume":"38","author":"L He","year":"2025","unstructured":"He L, Cheng X, Gu Y, Zhou C, Li Q, Zhang B, Cheng X, Tu S. Fruquintinib Combined With PD-1 Inhibitors for the Treatment of the Patients With Microsatellite Stability Metastatic Colorectal Cancer: Real-World Data. Clin Oncol (R Coll Radiol). 2025;38:103700.","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"16420_CR18","doi-asserted-by":"publisher","first-page":"851756","DOI":"10.3389\/fonc.2022.851756","volume":"12","author":"M Gou","year":"2022","unstructured":"Gou M, Qian N, Zhang Y, Yan H, Si H, Wang Z, Dai G. Fruquintinib in Combination With PD-1 Inhibitors in Patients With Refractory Non-MSI-H\/pMMR Metastatic Colorectal Cancer: A Real-World Study in China. Front Oncol. 2022;12:851756.","journal-title":"Front Oncol"},{"issue":"11","key":"16420_CR19","doi-asserted-by":"publisher","first-page":"3034","DOI":"10.21037\/tcr-23-867","volume":"12","author":"L Li","year":"2023","unstructured":"Li L, Wang T, Wu Z, Li Y, Ma H, Wang L, Lei S, Chen W. Fruquintinib in combination with sintilimab or TAS-102 as third-line or above treatment in patients with metastatic colorectal cancer: a real-world study. Transl Cancer Res. 2023;12(11):3034\u201344.","journal-title":"Transl Cancer Res"},{"key":"16420_CR20","doi-asserted-by":"publisher","first-page":"1480704","DOI":"10.3389\/fonc.2024.1480704","volume":"14","author":"C Wu","year":"2024","unstructured":"Wu C, Li S, Hou X. A real-world study: third-line treatment options for metastatic colorectal cancer. Front Oncol. 2024;14:1480704.","journal-title":"Front Oncol"},{"key":"16420_CR21","doi-asserted-by":"publisher","first-page":"1956","DOI":"10.3389\/fimmu.2020.01956","volume":"11","author":"Y Song","year":"2020","unstructured":"Song Y, Fu Y, Xie Q, Zhu B, Wang J, Zhang B. Anti-angiogenic Agents in Combination With Immune Checkpoint Inhibitors: A Promising Strategy for Cancer Treatment. Front Immunol. 2020;11:1956.","journal-title":"Front Immunol"},{"issue":"2","key":"16420_CR22","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1007\/s11523-024-01035-2","volume":"19","author":"BC Wang","year":"2024","unstructured":"Wang BC, Kuang BH, Lin GH. Lenvatinib Versus Atezolizumab Plus Bevacizumab in the First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Meta-Analysis of Real-World Studies. Target Oncol. 2024;19(2):203\u201312.","journal-title":"Target Oncol"},{"issue":"12","key":"16420_CR23","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1016\/S1470-2045(23)00469-2","volume":"24","author":"JM Llovet","year":"2023","unstructured":"Llovet JM, Kudo M, Merle P, Meyer T, Qin S, Ikeda M, Xu R, Edeline J, Ryoo BY, Ren Z, et al. Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial. Lancet Oncol. 2023;24(12):1399\u2013410.","journal-title":"Lancet Oncol"},{"issue":"10492","key":"16420_CR24","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.1016\/S0140-6736(25)00403-9","volume":"405","author":"T Yau","year":"2025","unstructured":"Yau T, Galle PR, Decaens T, Sangro B, Qin S, da Fonseca LG, Karachiwala H, Blanc JF, Park JW, Gane E, et al. Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma (CheckMate 9DW): an open-label, randomised, phase 3 trial. Lancet. 2025;405(10492):1851\u201364.","journal-title":"Lancet"},{"issue":"12","key":"16420_CR25","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1038\/s41571-024-00943-6","volume":"21","author":"CJM Williams","year":"2024","unstructured":"Williams CJM, Peddle AM, Kasi PM, Seligmann JF, Roxburgh CS, Middleton GW, Tejpar S. Neoadjuvant immunotherapy for dMMR and pMMR colorectal cancers: therapeutic strategies and putative biomarkers of response. Nat Rev Clin Oncol. 2024;21(12):839\u201351.","journal-title":"Nat Rev Clin Oncol"},{"key":"16420_CR26","doi-asserted-by":"crossref","unstructured":"Lin Z, Cai M, Zhang P, Li G, Liu T, Li X, Cai K, Nie X, Wang J, Liu J et al. Phase II, single-arm trial of preoperative short-course radiotherapy followed by chemotherapy and camrelizumab in locally advanced rectal cancer. J Immunother Cancer. 2021;9(11):e003554.","DOI":"10.1136\/jitc-2021-003554"},{"key":"16420_CR27","doi-asserted-by":"crossref","unstructured":"Cheng M, Jin M, Yang S, Zhao L, Yu D, Lin Z, Li P, Huang C, Liu J, Wang J et al. Effect of radiotherapy exposure on fruquintinib plus sintilimab treatment in refractory microsatellite stable metastatic colorectal cancer: a prospective observation study. J Immunother Cancer. 2025;13(1):e009415.","DOI":"10.1136\/jitc-2024-009415"},{"issue":"9","key":"16420_CR28","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1038\/s41571-022-00655-9","volume":"19","author":"RR Katipally","year":"2022","unstructured":"Katipally RR, Pitroda SP, Juloori A, Chmura SJ, Weichselbaum RR. The oligometastatic spectrum in the era of improved detection and modern systemic therapy. Nat Rev Clin Oncol. 2022;19(9):585\u201399.","journal-title":"Nat Rev Clin Oncol"},{"issue":"8","key":"16420_CR29","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1093\/annonc\/mdx175","volume":"28","author":"D Arnold","year":"2017","unstructured":"Arnold D, Lueza B, Douillard JY, Peeters M, Lenz HJ, Venook A, Heinemann V, Van Cutsem E, Pignon JP, Tabernero J, et al. Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials. Ann Oncol. 2017;28(8):1713\u201329.","journal-title":"Ann Oncol"},{"key":"16420_CR30","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.ejca.2016.10.007","volume":"70","author":"JW Holch","year":"2017","unstructured":"Holch JW, Ricard I, Stintzing S, Modest DP, Heinemann V. The relevance of primary tumour location in patients with metastatic colorectal cancer: A meta-analysis of first-line clinical trials. Eur J Cancer. 2017;70:87\u201398.","journal-title":"Eur J Cancer"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-026-16420-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-16420-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-16420-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T00:37:56Z","timestamp":1791506276000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12885-026-16420-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,15]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["16420"],"URL":"https:\/\/doi.org\/10.1186\/s12885-026-16420-5","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,15]]},"assertion":[{"value":"6 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"1212"}}